INTRODUCTION

38
Diverse malfunctions in the regulation of human matrix metalloproteinases, especially MMP-2 39 and MMP-9, play a key role in the development of a wide range of diseases including diabetes 40 mellitus, arthritis, cardiovascular diseases and -most of all -cancer (16, 5) . Recent oncology 41 research is therefore focusing on the specific inhibition of distinct MMPs as potential therapeutic 42 targets (3). Most of these inhibitors are peptidic succinates with a hydroxamate functionality, 43 binding to the zinc ion in the active site of the proteolytic enzyme (7,10,1). For example, 44 hydroxamate 1 (structure 1, Figure 1 ) shows a significant selectivity towards MMP-2, -8 and -9
Introduction of polar substituents (e.g. R = OH) onto the α-position of the hydroxamate group in 48 general results in higher solubility and oral bioavailability (27, 23) .
50
Nevertheless, early generations of MMP inhibitors (MMPIs) did not meet the high 51 expectations in clinical trials as poor inhibitor specificities caused massive side effects due to 52 the inhibition of non-MMP targets (16, 5, 24, 14) . Thus, identification of more specific inhibitors is Table T1 ). The resulting gene fusions contained the yeast ER signal 75 sequence of the S. cerevisiae pheromone α-factor (α-MF) at the 5' end followed by a signal 76 peptidase cleavage site, the respective proMMP and the SED1 gene at the 3' end. The freeze-dried form thus becoming applicable as easy and safe as soluble enzymes.
226
In conclusion, we established a safe, rapid, standardized and highly efficient yeast-based test 
